PubMed · 1995 · 107 citations · 0 references
Life SciencesNeurologyNeuroscienceClinical BiochemistryNeurochemistryNeurodegenerationCerebrospinal Fluid BiomarkersNeurochemical HomeostasisNeurodegenerative DiseasesNeurodegenerative DisordersParkinson DiseaseParkinsonian DisordersBiomarkers Of Parkinsonian DisordersCysteine MetabolismParkinson Disease Biomarkers
The study of Heafield et al. (1990) has prompted us to compare the levels of sulfate cysteine and homocysteine in the plasma of healthy subjects and of patients with Parkinson's disease treated by L-Dopa and dopa decarboxylase inhibitors. The levels of sulfate and cysteine in the plasma of controls and patients with Parkinson's disease were not statistically different but the level of homocysteine was higher in patients.